Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.31 |
| ▸ | MAOB | P27338 | 3/20 | 0.31 |
| ▸ | AHCY | P23526 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL792435 | 0.85 | LMNA (0.35) | KCNH2SCN9AHTR7 | |
| SCHEMBL804901 | 0.83 | PRKCA (0.43) | KCNH2SCN9AHTR2AHTR7HRH3 | |
| SCHEMBL14572861 | 0.82 | USP14 (0.42) | KCNH2SCN9A | |
| SCHEMBL12510266 | 0.81 | SCN9A (0.32) | KCNH2SCN9AHRH3 | |
| SCHEMBL792449 | 0.81 | ACHE (0.35) | KCNH2SCN9AHTR2AHRH3MAOB | |
| SCHEMBL792664 | 0.80 | CNR2 (0.34) | SCN9A | |
| SCHEMBL792442 | 0.80 | OPRM1 (0.34) | KCNH2DRD2DRD3 | |
| SCHEMBL804085 | 0.79 | PRKCA (0.43) | KCNH2SCN9AHTR2AHTR7HRH3 | |
| SCHEMBL12427889 | 0.79 | PRKCA (0.43) | KCNH2SCN9AHTR2AHTR7HRH3 | |
| SCHEMBL12427893 | 0.79 | PRKCA (0.43) | KCNH2SCN9AHTR2AHTR7HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | KCNH2 3813/4885SCN9A 3087/4885HTR2A 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.